Tesla Building Portable, Automated “RNA Microfactories” for CureVac's COVID-19 Vaccine
By HospiMedica International staff writers Posted on 03 Jul 2020 |
Illustration
Tesla Inc. (Palo Alto, CA, USA) is reportedly building mobile molecule printers to help make the potential COVID-19 vaccine being developed by CureVac AG (Tübingen, Germany).
A report by Reuters has said that CureVac has been working with Tesla Grohmann to develop the mobile printer technology. CureVac is developing portable, automated mRNA production units that it calls printers and which the electric-car maker’s Chief Executive Officer, Elon Musk, has described as “RNA microfactories”. These “microfactories” are being designed for shipping to remote locations, where they can produce its vaccine candidate and other mRNA-based therapies depending upon the formula programmed into the machine. In a Twitter thread, Musk said that the “microfactories” would be built at Tesla Grohmann Automation in Germany.
However, in the event of its vaccine candidate winning market approval, CureVac has production sites with regulatory approval in Germany with a capacity for producing hundreds of millions of doses. According to Reuters, CureVac is also building a new stationary site that could drive a tenfold increase in its output to billions of doses.
Related Links:
Tesla Inc.
CureVac AG
A report by Reuters has said that CureVac has been working with Tesla Grohmann to develop the mobile printer technology. CureVac is developing portable, automated mRNA production units that it calls printers and which the electric-car maker’s Chief Executive Officer, Elon Musk, has described as “RNA microfactories”. These “microfactories” are being designed for shipping to remote locations, where they can produce its vaccine candidate and other mRNA-based therapies depending upon the formula programmed into the machine. In a Twitter thread, Musk said that the “microfactories” would be built at Tesla Grohmann Automation in Germany.
However, in the event of its vaccine candidate winning market approval, CureVac has production sites with regulatory approval in Germany with a capacity for producing hundreds of millions of doses. According to Reuters, CureVac is also building a new stationary site that could drive a tenfold increase in its output to billions of doses.
Related Links:
Tesla Inc.
CureVac AG
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans